Stowe N, Schnermann J, Hermle M
Kidney Int. 1979 May;15(5):473-86. doi: 10.1038/ki.1979.63.
Tubuloglomerular feedback has been defined as a mechanism in which changes in distal tubular sodium chloride delivery induce changes in glomerular arteriolar resistance. Experiments were performed in rats to test the hypothesis that the alterations in vasomotor activity are controlled by local hormonal mechanisms. Early proximal flow rate (EPFR), used as an index of filtration rate, was assessed at loop perfusion rates of 10 and 40 nl/min and during zero loop flow before and during intravenous administration of agents which interfere with the reninangiotensin or adrenergic systems. During infusion of the angiotensin (A) antagonists [Sar1,Ile8-]-AII or [Me2,Gly1,Ile8]-AII at doses ranging from 4.8 to 30.6 micrograms/kg . min, feedback response, expressed as percent change of EPFR during loop flow elevation from 3 to 40 nl/min, fell from a mean of 47.6 +/- 3.3% to 33.2 +/- 2.9% (P less than 0.05). Likewise, after administration of the converting enzyme inhibitor SQ 20881 in a dose ranging between 5.5 and 34.0 mg/kg, feedback response decreased from 48.5 +/- 2.1% to 25.9 +/- 1.9% (P less than 0.001) and returned to 43.1 +/- 5.1% after the inhibitory effect of SQ 20881 on the pressure response to angiotensin I had disappeared. Luminal application of [Sar1,Thr2]-AII (5mM) or of SQ 20881 (5 or 10 mM) had no effect on the feedback response. A significant reduction in the feedback response was noted also during intravenous infusion of propranolol (46.4 +/- 3.2% vs. 29.0 +/- 2.8%, P less than 0.001), whereas 6-OH-dopamine, reserpine, or phenoxybenzamine had no detectable effect. Our results are in agreement with the concept that the renin-angiotensin system may mediate feedback-induced resistance changes. In addition, circulating catecholamines may, in some unknown manner, act as modulators of the feedback response.
管球反馈被定义为一种机制,即远端小管氯化钠输送的变化会引起肾小球小动脉阻力的改变。在大鼠身上进行了实验,以检验血管舒缩活动的改变受局部激素机制控制这一假说。在静脉注射干扰肾素 - 血管紧张素或肾上腺素能系统的药物之前和期间,分别以10和40 nl/min的襻灌注速率以及在零襻流量时,评估用作滤过率指标的早期近端流速(EPFR)。在以4.8至30.6微克/千克·分钟的剂量输注血管紧张素(A)拮抗剂[Sar1,Ile8]-AII或[Me2,Gly1,Ile8]-AII期间,反馈反应(表示为襻流量从3 nl/min升高至40 nl/min期间EPFR的百分比变化)从平均47.6±3.3%降至33.2±2.9%(P<0.05)。同样,在给予剂量范围为5.5至34.0毫克/千克的转化酶抑制剂SQ 20881后,反馈反应从48.5±2.1%降至25.9±1.9%(P<0.001),并且在SQ 20881对血管紧张素I压力反应的抑制作用消失后恢复至43.1±5.1%。管腔内应用[Sar1,Thr2]-AII(5 mM)或SQ 20881(5或10 mM)对反馈反应无影响。在静脉输注普萘洛尔期间也观察到反馈反应显著降低(46.4±3.2%对29.0±2.8%,P<0.001),而6 - 羟基多巴胺、利血平或酚苄明则无明显影响。我们的结果与肾素 - 血管紧张素系统可能介导反馈诱导的阻力变化这一概念一致。此外,循环中的儿茶酚胺可能以某种未知方式作为反馈反应的调节剂。